GlassScriptPhysician profile
Marlon B Kleinman
NPI 1255343521
$51,594.41
in general payments reported to CMS, 2019-2025
89 companies · $15K in 2025
The $15K reported for 2025 was more than what 91% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,539 · 2020: $4,456 · 2021: $5,280 · 2022: $5,090 · 2023: $4,248 · 2024: $15K · 2025: $15K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $21K · Food and Beverage: $11K · Travel and Lodging: $2,215 · Education: $341.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $20,800.00 |
| Food and Beverage | $10,872.35 |
| Travel and Lodging | $2,215.29 |
| Education | $340.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $23,342.80 | 2020-2025 | Ojjaara, Shingrix, Jemperli |
| Alnylam Pharmaceuticals INC. | $2,421.68 | 2019-2025 | Givlaari |
| Novartis Pharmaceuticals Corporation | $2,090.40 | 2019-2025 | Piqray, Kisqali |
| Astrazeneca Pharmaceuticals LP | $1,838.66 | 2019-2025 | Imfinzi, Calquence, Tagrisso |
| Adaptive Biotechnologies Corporation | $1,793.67 | 2021-2025 | Clonoseq |
| Pfizer INC. | $1,588.09 | 2019-2025 | |
| Amag Pharmaceuticals, INC. | $1,527.68 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $1,114.25 | 2019-2025 | Keytruda, Lynparza, Welireg |
| E.R. Squibb & Sons, L.L.C. | $1,098.93 | 2019-2025 | Opdualag, Opdivo, Eliquis |
| Janssen Biotech, INC. | $1,077.29 | 2019-2025 | Darzalex, Tecvayli, Rybrevant |
| Genzyme Corporation | $942.50 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $899.86 | 2019-2025 | Fruzaqla, Alunbrig, Vpriv |
| Celgene Corporation | $843.42 | 2019-2025 | Reblozyl, Pomalyst, Opdualag |
| Amgen INC. | $808.69 | 2019-2024 | Vectibix, Lumakras, Nplate |
| Incyte Corporation | $746.10 | 2019-2025 | Monjuvi, Jakafi |
Show all 88 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $737.35 | 2019-2025 | Columvi, Polivy, Lunsumio |
| Seagen INC. | $566.39 | 2019-2023 | Adcetris, Tukysa, Padcev |
| Abbvie INC. | $551.85 | 2020-2025 | |
| Emd Serono, INC. | $481.46 | 2019-2025 | Bavencio |
| Daiichi Sankyo INC. | $478.77 | 2019-2025 | Enhertu, Injectafer, Vanflyta |
| Lilly USA, LLC | $440.65 | 2019-2024 | Verzenio, Jaypirca |
| Pharmacyclics LLC, An Abbvie Company | $418.36 | 2019-2023 | Imbruvica, Epkinly |
| Astellas Pharma US INC | $391.91 | 2019-2025 | Xospata, Padcev, Xtandi |
| Regeneron Healthcare Solutions, INC. | $318.29 | 2019-2024 | Libtayo |
| Gilead Sciences, INC. | $272.53 | 2021-2025 | Trodelvy |
| Bayer Healthcare Pharmaceuticals INC. | $255.80 | 2019-2025 | |
| Blueprint Medicines Corporation | $203.12 | 2021-2024 | Ayvakit |
| Servier Pharmaceuticals LLC | $199.54 | 2022-2025 | |
| Dendreon Pharmaceuticals LLC | $191.96 | 2021-2024 | Provenge |
| Agios Pharmaceuticals, INC. | $185.34 | 2022-2025 | Pyrukynd |
| Tersera Therapeutics LLC | $160.12 | 2022-2025 | Quzyttir, Zoladex |
| Menarini Silicon Biosystems, INC. | $156.71 | 2022-2025 | Cellsearch |
| Eisai INC. | $153.95 | 2020-2024 | |
| Beigene USA, INC. | $149.46 | 2021-2023 | Brukinsa |
| Blue Earth Diagnostics | $148.33 | 2021-2024 | |
| Pharmacosmos Therapeutics INC. | $143.25 | 2022-2024 | Cosela, Monoferric |
| Array Biopharma INC | $130.74 | 2022-2025 | Lorbrena, Braftovi, Mektovi |
| Springworks Therapeutics, INC. | $126.28 | 2024-2025 | Ogsiveo |
| Geron Corporation | $124.98 | 2025 | Rytelo |
| Sobi, INC | $121.06 | 2022-2025 | |
| Alexion Pharmaceuticals, INC. | $115.54 | 2022-2025 | Ultomiris |
| Jazz Pharmaceuticals INC. | $113.82 | 2020-2024 | |
| Karyopharm Therapeutics INC. | $113.52 | 2021-2025 | Xpovio |
| Mirati Therapeutics, INC. | $112.69 | 2023-2024 | Krazati |
| Deciphera Pharmaceuticals INC. | $95.16 | 2022-2024 | Qinlock |
| Novocure INC. | $93.61 | 2020-2025 | Optune Lua (Novottf-200t) |
| Spectrum Pharmaceuticals INC. | $91.64 | 2023-2025 | Rolvedon |
| Exelixis INC. | $86.61 | 2020-2024 | Cabometyx |
| Kite Pharma, INC. | $83.62 | 2021-2025 | Yescarta |
| G1 Therapeutics, INC. | $74.60 | 2022-2023 | Cosela |
| Eusa Pharma (US) LLC | $71.07 | 2020-2022 | |
| Dova Pharmaceuticals | $63.44 | 2020-2021 | |
| Pharmaessentia USA Corporation | $63.37 | 2023-2024 | Besremi |
| Foundation Medicine, INC. | $62.67 | 2021-2023 | |
| Janssen Pharmaceuticals, INC | $53.02 | 2019-2023 | Xarelto |
| Azurity Pharmaceuticals, INC. | $50.45 | 2025 | Danziten |
| Acrotech Biopharma INC. | $49.93 | 2023-2024 | Beleodaq |
| Legend Biotech USA INC. | $48.28 | 2025 | Carvykti |
| Cti Biopharma Corp. | $47.60 | 2023 | Vonjo |
| Novo Nordisk INC | $47.13 | 2021-2024 | |
| Morphosys, US INC. | $45.17 | 2021-2022 | |
| Ge Healthcare | $44.44 | 2022 | |
| Melinta Therapeutics, LLC | $43.54 | 2024-2025 | Rezzayo, Orbactiv, Kimyrsa |
| Clovis Oncology, INC. | $43.36 | 2019-2022 | |
| Secura Bio, INC. | $43.29 | 2020-2021 | |
| Sumitomo Pharma America, INC. | $42.90 | 2023 | Orgovyx |
| Verastem, INC. | $42.82 | 2019-2020 | |
| Syndax Pharmaceuticals, INC. | $41.56 | 2025 | |
| Myriad Genetic Laboratories, INC. | $41.07 | 2021-2022 | |
| Tempus Ai, INC | $39.69 | 2024-2025 | Xt Cdx |
| Taiho Oncology, INC. | $38.53 | 2019-2025 | |
| Puma Biotechnology, INC. | $35.07 | 2021 | |
| Mylan Institutional INC. | $33.21 | 2019 | |
| Fennec Pharmaceuticals, INC. | $32.41 | 2024 | Pedmark |
| Global Blood Therapeutics, INC. | $24.38 | 2022 | |
| Genmab U.S., INC. | $22.51 | 2023 | Epkinly |
| Immunogen, INC. | $21.01 | 2023 | Elahere |
| Coherus Oncology, INC. | $20.15 | 2021 | |
| Aveo Pharmaceuticals, INC. | $20.00 | 2025 | |
| Epizyme, INC. | $19.90 | 2020 | |
| Ipsen Biopharmaceuticals, INC | $19.24 | 2025 | Onivyde |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.70 | 2019 | |
| Advanced Accelerator Applications | $15.82 | 2019 | |
| Janssen Scientific Affairs, LLC | $15.72 | 2020 | |
| Invivyd INC | $14.44 | 2025 | Pemgarda |
| Immunomedics, INC. | $13.57 | 2020 | |
| Rigel Pharmaceuticals, INC. | $12.08 | 2020 | |
| Fortovia Therapeutics, INC. | $10.84 | 2020 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marlon Kleinman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
The CSV has this whole record: totals, yearly figures, every listed company, payment types, and product associations.
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.